Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Cue Biopharma, Inc. (CUE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/19/2020 |
8-K
| Quarterly results|
Docs:
|
"Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights CAMBRIDGE, Mass., May 19, 2020 — Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the first quarter 2020. “We have successfully maintained momentum in meeting our business goals and clinical trial objectives for the first quarter and early second quarter of 2020, despite the rapid onset of COVID-19 and the many challenges it has presented,” said Daniel Passeri, chief executive officer of Cue Biopharma. “I am grateful for the dedication of the Cue Biopharma team during this pandemic as we continue to..." |
|
| 11/12/2019 |
8-K
| Quarterly results |
|
|